| JELINEK, Tomas, Tereza SEVCIKOVA, David ZIHALA, Tereza POPKOVA, Veronika KAPUSTOVA, Lucie BROSKEVICOVA, Lenka CAPKOVA, Lucie ŘÍHOVÁ, Renata BEZDĚKOVÁ, Sabina ŠEVČÍKOVÁ, Vladimir ZIDLIK, Martin HAVEL, Hana PLONKOVA, Alexandra JUNGOVA, Jiri MINARIK, Martin ŠTORK, Luděk POUR, Petr PAVLICEK, Ivan SPICKA, Vladimir MAISNAR, Jakub RADOCHA, Michal SIMICEK and Roman HAJEK. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia. London: Nature Publishing Group, 2022, vol. 36, No 1, p. 288-291. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/s41375-021-01343-w. |
Other formats:
BibTeX
LaTeX
RIS
@article{1787325,
author = {Jelinek, Tomas and Sevcikova, Tereza and Zihala, David and Popkova, Tereza and Kapustova, Veronika and Broskevicova, Lucie and Capkova, Lenka and Říhová, Lucie and Bezděková, Renata and Ševčíková, Sabina and Zidlik, Vladimir and Havel, Martin and Plonkova, Hana and Jungova, Alexandra and Minarik, Jiri and Štork, Martin and Pour, Luděk and Pavlicek, Petr and Spicka, Ivan and Maisnar, Vladimir and Radocha, Jakub and Simicek, Michal and Hajek, Roman},
article_location = {London},
article_number = {1},
doi = {http://dx.doi.org/10.1038/s41375-021-01343-w},
keywords = {daratumumab; multiple myeloma; extramedullary disease; efficacy},
language = {eng},
issn = {0887-6924},
journal = {Leukemia},
title = {Limited efficacy of daratumumab in multiple myeloma with extramedullary disease},
url = {https://www.nature.com/articles/s41375-021-01343-w},
volume = {36},
year = {2022}
}
TY - JOUR
ID - 1787325
AU - Jelinek, Tomas - Sevcikova, Tereza - Zihala, David - Popkova, Tereza - Kapustova, Veronika - Broskevicova, Lucie - Capkova, Lenka - Říhová, Lucie - Bezděková, Renata - Ševčíková, Sabina - Zidlik, Vladimir - Havel, Martin - Plonkova, Hana - Jungova, Alexandra - Minarik, Jiri - Štork, Martin - Pour, Luděk - Pavlicek, Petr - Spicka, Ivan - Maisnar, Vladimir - Radocha, Jakub - Simicek, Michal - Hajek, Roman
PY - 2022
TI - Limited efficacy of daratumumab in multiple myeloma with extramedullary disease
JF - Leukemia
VL - 36
IS - 1
SP - 288-291
EP - 288-291
PB - Nature Publishing Group
SN - 08876924
KW - daratumumab
KW - multiple myeloma
KW - extramedullary disease
KW - efficacy
UR - https://www.nature.com/articles/s41375-021-01343-w
N2 - The treatment of multiple myeloma (MM) has changed substantially during the past two decades. The incorporation of novel agents into therapeutic strategies has resulted in prolonged overall survival of MM patients with approximately 15% of them being considered operationally cured.
ER -
JELINEK, Tomas, Tereza SEVCIKOVA, David ZIHALA, Tereza POPKOVA, Veronika KAPUSTOVA, Lucie BROSKEVICOVA, Lenka CAPKOVA, Lucie ŘÍHOVÁ, Renata BEZDĚKOVÁ, Sabina ŠEVČÍKOVÁ, Vladimir ZIDLIK, Martin HAVEL, Hana PLONKOVA, Alexandra JUNGOVA, Jiri MINARIK, Martin ŠTORK, Luděk POUR, Petr PAVLICEK, Ivan SPICKA, Vladimir MAISNAR, Jakub RADOCHA, Michal SIMICEK and Roman HAJEK. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. \textit{Leukemia}. London: Nature Publishing Group, 2022, vol.~36, No~1, p.~288-291. ISSN~0887-6924. Available from: https://dx.doi.org/10.1038/s41375-021-01343-w.
|
